Literature DB >> 35972597

Differential molecular mechanistic behavior of HDACs in cancer progression.

Tashvinder Singh1, Prabhsimran Kaur1, Paramdeep Singh2, Sandeep Singh3, Anjana Munshi4.   

Abstract

Genetic aberration including mutation in oncogenes and tumor suppressor genes transforms normal cells into tumor cells. Epigenetic modifications work concertedly with genetic factors in controlling cancer development. Histone acetyltransferases (HATs), histone deacetylases (HDACs), DNA methyltransferases (DNMTs) and chromatin structure modifier are prospective epigenetic regulators. Specifically, HDACs are histone modifiers regulating the expression of genes implicated in cell survival, growth, apoptosis, and metabolism. The majority of HDACs are highly upregulated in cancer, whereas some have a varied function and expression in cancer progression. Distinct HDACs have a positive and negative role in controlling cancer progression. HDACs are also significantly involved in tumor cells acquiring metastatic and angiogenic potential in order to withstand the anti-tumor microenvironment. HDACs' role in modulating metabolic genes has also been associated with tumor development and survival. This review highlights and discusses the molecular mechanisms of HDACs by which they regulate cell survival, apoptosis, metastasis, invasion, stemness potential, angiogenesis, and epithelial to mesenchymal transitions (EMT) in tumor cells. HDACs are the potential target for anti-cancer drug development and various inhibitors have been developed and FDA approved for a variety of cancers. The primary HDAC inhibitors with proven anti-cancer efficacy have also been highlighted in this review.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Angiogenesis; Cancer; Histone deacetylases; Metabolism; Metastasis; Stemness potential

Mesh:

Substances:

Year:  2022        PMID: 35972597     DOI: 10.1007/s12032-022-01770-4

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.738


  169 in total

Review 1.  Epigenetic Targets and their Inhibitors in Cancer Therapy.

Authors:  Le Zhao; Yong-Tao Duan; Ping Lu; Zhi-Juan Zhang; Xiao-Ke Zheng; Jun-Lei Wang; Wei-Sheng Feng
Journal:  Curr Top Med Chem       Date:  2018       Impact factor: 3.295

Review 2.  Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer.

Authors:  Christos Damaskos; Nikolaos Garmpis; Serena Valsami; Michael Kontos; Eleftherios Spartalis; Theodoros Kalampokas; Emmanouil Kalampokas; Antonios Athanasiou; Demetrios Moris; Afrodite Daskalopoulou; Spyridon Davakis; Gerasimos Tsourouflis; Konstantinos Kontzoglou; Despina Perrea; Nikolaos Nikiteas; Dimitrios Dimitroulis
Journal:  Anticancer Res       Date:  2017-01       Impact factor: 2.480

3.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

4.  Non-histone substrates of histone deacetylases as potential therapeutic targets in epilepsy.

Authors:  Sonali Kumar; Diksha Attrish; Arpna Srivastava; Jyotirmoy Banerjee; Manjari Tripathi; P Sarat Chandra; Aparna Banerjee Dixit
Journal:  Expert Opin Ther Targets       Date:  2020-12-04       Impact factor: 6.902

Review 5.  Co-repressor, co-activator and general transcription factor: the many faces of the Sin3 histone deacetylase (HDAC) complex.

Authors:  Grace E Adams; Aditya Chandru; Shaun M Cowley
Journal:  Biochem J       Date:  2018-12-14       Impact factor: 3.857

6.  Role of HDAC1 in the progression of gastric cancer and the correlation with lncRNAs.

Authors:  Zhiqiang Yu; Jun Zeng; Hui Liu; Tian Wang; Ziqi Yu; Jianyong Chen
Journal:  Oncol Lett       Date:  2019-01-23       Impact factor: 2.967

Review 7.  A short guide to histone deacetylases including recent progress on class II enzymes.

Authors:  Suk-Youl Park; Jeong-Sun Kim
Journal:  Exp Mol Med       Date:  2020-02-19       Impact factor: 8.718

8.  Hallmarks of cancer-the new testament.

Authors:  Sasi S Senga; Richard P Grose
Journal:  Open Biol       Date:  2021-01-20       Impact factor: 6.411

9.  Cancer Statistics, 2020: Report From National Cancer Registry Programme, India.

Authors:  Prashant Mathur; Krishnan Sathishkumar; Meesha Chaturvedi; Priyanka Das; Kondalli Lakshminarayana Sudarshan; Stephen Santhappan; Vinodh Nallasamy; Anish John; Sandeep Narasimhan; Francis Selvaraj Roselind
Journal:  JCO Glob Oncol       Date:  2020-07

Review 10.  Valproic Acid and Breast Cancer: State of the Art in 2021.

Authors:  Anna Wawruszak; Marta Halasa; Estera Okon; Wirginia Kukula-Koch; Andrzej Stepulak
Journal:  Cancers (Basel)       Date:  2021-07-07       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.